Skip to main content
 

Biosimilars Forum Opposes Efforts to Prohibit Biosimilars From Receiving Pass-Through Payment Status

Washington, D.C., February 22, 2018 - The Biosimilars Forum opposes any legislative or regulatory efforts to prohibit biosimilars from receiving "pass-through" payment status in the Medicare Part B program. The Forum supports the CY 2018 Centers for Medicare & Medicaid Services (CMS) policy that each qualifying biosimilar is eligible for Hospital Outpatient Prospective Payment System ("OPPS") pass-through payment status, not just the first biosimilar biological product for a reference product. Such a policy encourages innovation and advances a stronger marketplace, access, and provider and patient choices.


About the Biosimilars Forum

The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.

To learn more about biosimilars, the Forum, and how to get involved, visit BiosimilarsForum.org, @USbiosimilars, or Facebook/USBiosimilars to follow related conversations and join the dialogue.

Contact:
Aimee Steel Lubin
202.828.1895
aimee.lubin@hklaw.com

Date

Thursday, February 22, 2018